Scalper1 News
Gilead Sciences’ (GILD) newly approved hepatitis C drug Sovaldi came under fire for its price from pharmacy benefit manager Express Scripts (ESRX) Tuesday, as rival AbbVie (ABBV) reported good data for its competing drug candidate. Gilead’s stock dropped while AbbVie’s rose on the stock market today. Bloomberg reporter Drew Armstrong said on Twitter that Express Scripts’ chief medical officer, Steve Miller, told him that the convenience of Scalper1 News
Scalper1 News